Ask a Question

Ask your question and our customer service team will answer it as soon as they can. Questions that do not contain personal information may be posted to our help center to be of service to others

* Required field

Your Email Address *

Please enter a valid email address.

Choose a Topic *

Tell us your question and any additional information *

Please enter all required fields.

Find a Clinical Trial

Researching Blood Cancer and blood conditions

Blood cancers form in the bone marrow where blood is made, or in the lymphatic system, which protects us from infections.

Jump to Studies

Blood Cancer Clinical Trials

We are currently investigating experimental medications for Blood Cancers: Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome and Myelofibrosis and Blood Conditions: Beta-Thalassemia.

Leukemia is a cancer of the blood and bone marrow caused by too many white blood cells, leukemia takes on several forms and can occur in both children and adults.
Lymphomas are blood cancers that target the immune system.
Multiple Myeloma is a type of blood cancer which forms in plasma cells.
Myelodysplastic Syndrome is a type of cancer in which the bone marrow does not make enough healthy blood cells (white blood cells, red blood cells and platelets) and there are abnormal cells in the blood and/or bone marrow.
Myelofibrosis is a disorder in which the bone marrow is replaced by fibrous tissue.
Beta-Thalassemia is an inherited blood disorder that causes the body to make less hemoglobin.

divider

Thank you for Considering a Clinical Trial

Below you will find clinical trials that are either currently recruiting patients (noted as Recruiting) or starting to recruit patients soon (noted as Not Yet Recruiting).

Here are some options for you to find more information:

Browse the trials available on your own and Click on View Trial Details for more information, including locations that are recruiting patients.
- or -
Let us help you find a trial: Check Your Eligibility and answer a few questions to determine if there is a trial that might be right for you.

Leukemia Trials

AZA-MDS-006

Recruiting

Connect® Myeloid Disease Registry

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

CC-90009-AML-002

Recruiting

A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

CA097-001

Recruiting

A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

View Trial Details

Lymphoma Trials

JCAR017-FOL-001

Recruiting

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

Juno Therapeutics and Celgene are wholly owned subsidiaries of Bristol-Myers Squibb Company

View Trial Details

CC-99282-NHL-001

Recruiting

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

CC-220-DLBCL-001

Recruiting

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

NDS-DLBCL-003

Recruiting

Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

CA097-001

Recruiting

A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

View Trial Details

Multiple Myeloma Trials

CA204-008

Recruiting

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

View Trial Details

CC-220-MM-001

Recruiting

A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

CC-92480-MM-001

Recruiting

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

BB2121-MM-002

Recruiting

An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

CC-92480-MM-002

Recruiting

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

CC-99712-MM-001

Recruiting

A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

CC-95266-MM-001

Recruiting

A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma

Juno Therapeutics and Celgene are wholly owned subsidiaries of Bristol-Myers Squibb Company

View Trial Details

CC-92328-MM-001

Recruiting

Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

CC-220-MM-002

Recruiting

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

CA057-003

Recruiting

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

View Trial Details

CA057-001

Recruiting

A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

View Trial Details

CA057-008

Recruiting

A Study to Evaluate CC-92480 in Combination With Carfilzomib and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

View Trial Details

Myelofibrosis Trials

AZA-MDS-006

Recruiting

Connect® Myeloid Disease Registry

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

ACE-536-MF-002

Recruiting

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

CA011-023

Recruiting

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

View Trial Details

Myelodysplastic Syndrome Trials

AZA-MDS-006

Recruiting

Connect® Myeloid Disease Registry

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

CC-90009-AML-001

Recruiting

A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

CC-91633-AML-001

Recruiting

Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

CA055-026

Recruiting

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

View Trial Details

CA059-001

Recruiting

A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes

View Trial Details

Beta-Thalassemia Trials

ACE-536-B-THAL-004

Recruiting

Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants Who Require Regular RBC Transfusions Due to Beta (β)-Thalassemia.

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

What are you thankful for?

Explore Blood Cancer Resources

More About Blood Cancer

By the numbers - More than 1 million new blood cancer cases are expected to be diagnosed globally in 2020, accounting for approximately 6% of all new cancer cases.

Learn More

Leukemia Statistics

Did You Know? Video Series

Bristol Myers Squibb is not affiliated with the creators of this content. The information provided here is for informational purposes only and is not meant to replace a physician's medical advice or imply endorsement. Content in this video may speak to medical topics that are not necessarily related to clinical trials.

Source: NIH (National Institute of Heath) – used with permission 2:53

SELECTED SUPPORT ORGANIZATIONS AND DISEASE INFORMATION

Bristol Myers Squibb is not affiliated with nor endorses any of the listed organizations. The information/links provided by Bristol Myers Squibb are meant for informational purposes only and are not meant to replace a physician's medical advice or imply endorsement. This is not an exhaustive list of resources for this condition. There may be others that you may wish to explore.

National Cancer Institute Multiple Myeloma Overview

divider

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Live support is available 24/7 - Call 855-907-3286 or email clinical.trials@bms.com

Have questions? Live support is available 24/7 -

Call 855-907-3286 or email clinical.trials@bms.com